Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Portfolio Pulse from
Syndax Pharmaceuticals announced positive results from its AUGMENT-101 trial for revumenib in treating relapsed or refractory mNPM1 AML. The trial met its primary endpoint with a 23% CR/CRh rate and a 47% ORR. The drug showed a favorable safety profile, with only 5% discontinuation due to adverse events. A sNDA filing is expected in 1H25.
November 12, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharmaceuticals announced positive results from its AUGMENT-101 trial for revumenib, showing a 23% CR/CRh rate in mNPM1 AML patients. The drug demonstrated a favorable safety profile, with only 5% discontinuation due to adverse events. A sNDA filing is anticipated in 1H25.
The positive trial results for revumenib in treating mNPM1 AML are likely to boost investor confidence in Syndax Pharmaceuticals. Meeting the primary endpoint and demonstrating a favorable safety profile are significant achievements that could lead to regulatory approval and future revenue. The anticipated sNDA filing in 1H25 further supports a positive outlook for the company's stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100